Abbreviations
AMR, antimicrobial resistance; AMS, antimicrobial stewardship; CRE, carbapenem-resistant Enterobacterales; GNB, Gram-negative bacteria; IV, intravenous; KPC, Klebsiella pneumoniae carbapenemase; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci.
References:
- QUOFENIX 450 mg tablets SmPC.
- QUOFENIX 300 mg powder for concentrate for solution for infusion SmPC.
- Giordano PA et al. Clin Infect Dis 2019; 68(Suppl 3): S223–S232.
- VABOREM 1g/1g powder for concentrate for solution for infusion SmPC.
- Hecker SJ et al. J Med Chem 2015; 58: 3682–3692.
- Dhillon S. Drugs 2018; 78: 1259–1270.
- Toussaint KA et al. Ann Pharmacother 2015; 49: 86–98.
- Pogue JM et al. Clin Infect Dis 2019; 68: 519–524.
- TENKASI 400 mg powder for concentrate for solution for infusion SmPC.
- Brade KD et al. Infect Dis Ther 2016; 5: 1–15.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to A. Menarini Farmaceutica Internazionale SRL. Phone 0800 085 8678 or email: [email protected]
These medicinal products are subject to additional monitoring.